On December 12, 2024, Lumos Pharma, a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures (DPV) announced the successful completion the previously announced tender offer for Lumos Pharma's shares, with 75.62 percent of shares tendered. The purchase price of $4.25 per share represents a total equity value of approximately $38 million. Following the acceptance of the shares offered in the tender, DPV successfully acquired enough shares of Lumos Pharma's common stock to finalize the merger. Wilson Sonsini Goodrich & Rosati advised Lumos Pharma on the transaction.

Lumos Pharma will operate as a standalone business of DPV from its current headquarters in Austin, Texas. The common stock of Lumos Pharma has ceased to trade on NASDAQ.

The Wilson Sonsini team that advised Lumos Pharma on the transaction includes Rob Suffoletta, Nathan Robinson, Tamara Labanowski, and Varun Lella.

For more information, please see Lumos Pharma's and DPV's joint news release.